Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 12Ovarian Neoplasms 11Fallopian Tube Neoplasms 10Carcinoma, Non-Small-Cell Lung 7Pancreatic Neoplasms 5Brenner Tumor 5Lung Neoplasms 4Endometrial Neoplasms 4Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Carcinoma 3Adenocarcinoma of Lung 3Oropharyngeal Neoplasms 2Neurotoxicity Syndromes 2Mouth Neoplasms 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Carcinosarcoma 2Carcinoma, Transitional Cell 2Vomiting 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Recurrent Uterine Corpus Carcinoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Cancer Resectable 1Pancreatic Adenocarcinoma 1Pancreas Adenocarcinoma 1Pain 1Ovarian Germ Cell Cancer 1

Interventions

Gemcitabine 2Taxes 1Radiotherapy, Intensity-Modulated 1Irinotecan 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Pancreatic Adenocarcinoma × Taxes × Clear all
NCT04835064 2021-04-08

Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy.

Fudan University

Phase 3 Unknown
600 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡